These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22278753)

  • 1. Use of partial AUC to demonstrate bioequivalence of Zolpidem Tartrate Extended Release formulations.
    Lionberger RA; Raw AS; Kim SH; Zhang X; Yu LX
    Pharm Res; 2012 Apr; 29(4):1110-20. PubMed ID: 22278753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanistic investigation of the negative food effect of modified release zolpidem.
    Andreas CJ; Pepin X; Markopoulos C; Vertzoni M; Reppas C; Dressman JB
    Eur J Pharm Sci; 2017 May; 102():284-298. PubMed ID: 28286289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Novel Oral Cavity Compartmental Absorption and Transit Model for Sublingual Administration: Illustration with Zolpidem.
    Xia B; Yang Z; Zhou H; Lukacova V; Zhu W; Milewski M; Kesisoglou F
    AAPS J; 2015 May; 17(3):631-42. PubMed ID: 25716146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
    Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic effects of simultaneous administration of single-dose gabapentin 500 mg and zolpidem tartrate 10 mg in healthy volunteers: a randomized, open-label, crossover trial.
    Galitz LA; Jayawardena S; Furey SA
    Drugs R D; 2015 Mar; 15(1):71-7. PubMed ID: 25567214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zolpidem extended-release: a single insomnia treatment option for sleep induction and sleep maintenance symptoms.
    Barkin RL
    Am J Ther; 2007; 14(3):299-305. PubMed ID: 17515707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of physiologically based absorption modeling in implementing Quality by Design in drug development.
    Zhang X; Lionberger RA; Davit BM; Yu LX
    AAPS J; 2011 Mar; 13(1):59-71. PubMed ID: 21207216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adults.
    Greenblatt DJ; Harmatz JS; Roth T; Singh NN; Moline ML; Harris SC; Kapil RP
    Clin Ther; 2013 May; 35(5):604-11. PubMed ID: 23541711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo.
    Greenblatt DJ; Legangneux E; Harmatz JS; Weinling E; Freeman J; Rice K; Zammit GK
    J Clin Pharmacol; 2006 Dec; 46(12):1469-80. PubMed ID: 17101746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of PBPK/PD to establish clinically relevant dissolution specifications for zolpidem immediate release tablets.
    Paraiso RLM; Rose RH; Fotaki N; McAllister M; Dressman JB
    Eur J Pharm Sci; 2020 Dec; 155():105534. PubMed ID: 32871212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: examination of current bioequivalence criteria.
    Shram MJ; Quinn AM; Chen N; Faulknor J; Luong D; Sellers EM; Endrenyi L
    Clin Ther; 2012 May; 34(5):1170-81. PubMed ID: 22512898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
    Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
    Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improve sleep maintenance.
    Weinling E; McDougall S; Andre F; Bianchetti G; Dubruc C
    Fundam Clin Pharmacol; 2006 Aug; 20(4):397-403. PubMed ID: 16867025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of partial area under the curve and maximum concentrations in assessing the bioequivalence of long-acting injectable formulation of exenatide_A sensitivity analysis.
    Wang HJ; Hsu LF
    Eur J Pharm Sci; 2024 Apr; 195():106718. PubMed ID: 38316168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
    Jantratid E; Prakongpan S; Amidon GL; Dressman JB
    Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of zolpidem from sublingual zolpidem tartrate tablets in healthy elderly versus non-elderly subjects.
    Greenblatt DJ; Harmatz JS; Singh NN; Steinberg F; Roth T; Harris SC; Kapil RP
    Drugs Aging; 2014 Oct; 31(10):731-6. PubMed ID: 25246162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel zolpidem formulations.
    Owen RT
    Drugs Today (Barc); 2009 May; 45(5):395-400. PubMed ID: 19584967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo bioequivalence and in vitro similarity factor (f2) for dissolution profile comparisons of extended release formulations: how and when do they match?
    Duan JZ; Riviere K; Marroum P
    Pharm Res; 2011 May; 28(5):1144-56. PubMed ID: 21287250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of food on pharmacokinetics of zolpidem from fast dissolving sublingual zolpidem tartrate tablets.
    Greenblatt DJ; Harmatz JS; Singh NN; Roth T; Harris SC; Kapil RP
    J Clin Pharmacol; 2013 Nov; 53(11):1194-8. PubMed ID: 23939537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of new partial AUC parameters for evaluating the bioequivalence of prolonged-release formulations.
    Boily M; Dussault C; Massicotte J; Guibord P; Lefebvre M
    Eur J Pharm Sci; 2015 Jan; 66():70-7. PubMed ID: 25312344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.